MarketCap
Facebook
X
TelegramAnnual report 2024
added 05-07-2025
Axon Enterprise Cash and Cash Equivalents 2011-2026 | AXON
Annual Cash and Cash Equivalents Axon Enterprise
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 455 M | 599 M | 354 M | 356 M | 155 M | 172 M | 349 M | 75.1 M | 40.7 M | 59.5 M | 48.4 M | 42.3 M | 36.1 M | 21.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 599 M | 21.3 M | 197 M |
Quarterly Cash and Cash Equivalents Axon Enterprise
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.09 B | 455 M | 404 M | 406 M | 474 M | 263 M | 354 M | 148 M | 213 M | 386 M | 356 M | 282 M | 266 M | 155 M | 156 M | 155 M | 155 M | 155 M | 172 M | 172 M | 172 M | 172 M | 349 M | 349 M | 349 M | 349 M | 75.1 M | 75.1 M | 75.1 M | 75.1 M | 40.7 M | 40.7 M | 40.7 M | 40.7 M | 59.5 M | 59.5 M | 59.5 M | 59.5 M | 48.4 M | 48.4 M | 48.4 M | 48.4 M | 42.3 M | 42.3 M | 42.3 M | 42.3 M | 36.1 M | 36.1 M | 36.1 M | 36.1 M | 21.3 M | 21.3 M | 21.3 M | 21.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.09 B | 21.3 M | 171 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
129 M | $ 3.46 | 1.72 % | $ 1.03 B |  Canada |
 |
Altimmune
ALT
|
43.8 M | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
9.13 B | $ 350.07 | 0.63 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 19.49 | -0.05 % | $ 911 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
616 M | $ 220.18 | -0.77 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Aurinia Pharmaceuticals
AUPH
|
80.2 M | $ 14.83 | 5.78 % | $ 1.99 B | Canada |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.42 | 3.64 % | $ 362 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Axsome Therapeutics
AXSM
|
323 M | $ 154.69 | -1.42 % | $ 7.7 B | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
1.31 B | $ 54.66 | 0.97 % | $ 10.5 B | USA |
 |
Benitec Biopharma
BNTC
|
97.7 M | $ 11.25 | 2.46 % | $ 463 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
88.3 M | $ 12.74 | - | $ 768 M | USA |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Coherus BioSciences
CHRS
|
88.9 M | $ 1.59 | 4.28 % | $ 186 M | USA |
 |
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | USA |
 |
Cellectis S.A.
CLLS
|
61.5 M | $ 3.38 | 1.05 % | $ 116 M | France |
 |
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
143 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
7.8 M | $ 2.13 | 1.9 % | $ 199 M | Israel |
 |
Denali Therapeutics
DNLI
|
175 M | $ 20.96 | 3.89 % | $ 3.45 B | USA |
 |
Dyadic International
DYAI
|
6.52 M | $ 0.86 | -8.51 % | $ 24.8 M | USA |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
145 M | $ 6.33 | 1.28 % | $ 456 K | USA |